Long-term Follow-up at 10 Years of Patients Enrolled in the Fingolimod Phase II Program in Relapsing Multiple Sclerosis (MS)
Phase of Trial: Phase IV
Latest Information Update: 27 Mar 2017
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms ACROSS
- Sponsors Novartis
- 15 Jan 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 15 Oct 2015 Planned number of patients changed from 281 to 228 as reported by ClinicalTrials.gov record.
- 15 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.